- Home
- UCAR vs BCDA Comparison
UCAR vs BCDA Comparison
Compare UCAR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- BCDA
- Stock Information
- Founded
- UCAR 2013
- BCDA N/A
- Country
- UCAR China
- BCDA United States
- Employees
- UCAR N/A
- BCDA N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- BCDA Health Care
- Exchange
- UCAR Nasdaq
- BCDA Nasdaq
- Market Cap
- UCAR 10.0M
- BCDA 11.3M
- IPO Year
- UCAR 2023
- BCDA N/A
- Fundamental
- Price
- UCAR $1.96
- BCDA $2.16
- Analyst Decision
- UCAR Strong Buy
- BCDA Strong Buy
- Analyst Count
- UCAR 1
- BCDA 1
- Target Price
- UCAR $5.00
- BCDA $25.00
- AVG Volume (30 Days)
- UCAR 23.7K
- BCDA 42.7K
- Earning Date
- UCAR 10-07-2025
- BCDA 11-12-2025
- Dividend Yield
- UCAR N/A
- BCDA N/A
- EPS Growth
- UCAR N/A
- BCDA N/A
- EPS
- UCAR N/A
- BCDA N/A
- Revenue
- UCAR $6,067,871.00
- BCDA N/A
- Revenue This Year
- UCAR N/A
- BCDA N/A
- Revenue Next Year
- UCAR N/A
- BCDA N/A
- P/E Ratio
- UCAR N/A
- BCDA N/A
- Revenue Growth
- UCAR 124.09
- BCDA N/A
- 52 Week Low
- UCAR $1.74
- BCDA $1.63
- 52 Week High
- UCAR $9.43
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- UCAR 36.51
- BCDA 59.44
- Support Level
- UCAR $1.94
- BCDA $1.90
- Resistance Level
- UCAR $2.14
- BCDA $2.29
- Average True Range (ATR)
- UCAR 0.11
- BCDA 0.09
- MACD
- UCAR 0.04
- BCDA 0.04
- Stochastic Oscillator
- UCAR 20.17
- BCDA 66.67
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).